A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering
Jingen Zhu, Neeti Ananthaswamy, Swati Jain, Himanshu Batra, Wei-Chun Tang, Douglass A. Lewry, Michael Richards, Sunil A. David, Paul B. Kilgore, Jian Sha, Aleksandra Drelich, Chien‐Te K. Tseng, Ashok K. Chopra, Venigalla B. Rao
Abstract
2 immunoglobulin G subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new nanovaccine design framework might allow the rapid deployment of effective adjuvant-free phage-based vaccines against any emerging pathogen in the future.
Topics & Concepts
CRISPRMultiplexVirologyBacteriophageComputational biologyCoronavirusEpitopeAdjuvantBiologyGenomeGeneCoronavirus disease 2019 (COVID-19)AntibodyMedicineGeneticsImmunologyInfectious disease (medical specialty)Escherichia coliDiseasePathologySARS-CoV-2 and COVID-19 ResearchBacteriophages and microbial interactionsCRISPR and Genetic Engineering